Investors purchased shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on weakness during trading hours on Thursday. $57.27 million flowed into the stock on the tick-up and $39.55 million flowed out of the stock on the tick-down, for a money net flow of $17.72 million into the stock. Of all companies tracked, Regeneron Pharmaceuticals had the 24th highest net in-flow for the day. Regeneron Pharmaceuticals traded down ($0.81) for the day and closed at $410.87

A number of equities research analysts recently commented on REGN shares. Robert W. Baird reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Monday, May 16th. Vetr upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $429.64 price target for the company in a report on Monday, June 13th. Sanford C. Bernstein reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, June 30th. Leerink Swann restated an “outperform” rating and issued a $530.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 1st. Finally, Canaccord Genuity restated a “hold” rating and issued a $450.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and thirteen have given a buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Hold” and a consensus price target of $477.00.

The stock’s 50 day moving average price is $397.99 and its 200 day moving average price is $388.64. The company has a market cap of $42.99 billion and a PE ratio of 64.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.17. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.24 billion. The firm’s revenue for the quarter was up 21.4% compared to the same quarter last year. During the same quarter last year, the business posted $2.89 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals Inc. will post $10.95 earnings per share for the current year.

In related news, Director Arthur F. Ryan sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $396.64, for a total value of $396,640.00. Following the completion of the sale, the director now directly owns 40,500 shares in the company, valued at $16,063,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Sanofi acquired 64,731 shares of the firm’s stock in a transaction that occurred on Tuesday, June 14th. The stock was purchased at an average price of $363.86 per share, with a total value of $23,553,021.66. The disclosure for this purchase can be found here.

Several hedge funds have recently added to or reduced their stakes in REGN. Schwab Charles Investment Management Inc. increased its stake in Regeneron Pharmaceuticals by 16.8% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 218,216 shares of the biopharmaceutical company’s stock valued at $118,463,000 after buying an additional 31,441 shares during the last quarter. Calvert Investment Management Inc. increased its position in shares of Regeneron Pharmaceuticals by 26.4% in the fourth quarter. Calvert Investment Management Inc. now owns 4,027 shares of the biopharmaceutical company’s stock worth $2,186,000 after buying an additional 840 shares in the last quarter. American International Group Inc. increased its position in shares of Regeneron Pharmaceuticals by 0.4% in the fourth quarter. American International Group Inc. now owns 38,434 shares of the biopharmaceutical company’s stock worth $20,865,000 after buying an additional 136 shares in the last quarter. BlackRock Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 8.3% in the fourth quarter. BlackRock Advisors LLC now owns 262,466 shares of the biopharmaceutical company’s stock worth $142,485,000 after buying an additional 20,224 shares in the last quarter. Finally, KBC Group NV increased its position in shares of Regeneron Pharmaceuticals by 13.8% in the fourth quarter. KBC Group NV now owns 14,604 shares of the biopharmaceutical company’s stock worth $7,928,000 after buying an additional 1,767 shares in the last quarter.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.